SLC25A20

Across TCGA pan-cancer cohorts, SLC25A20 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC25A20 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SLC25A20 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC25A20 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

GBM, LSCC, and HNSC are the cancer types where SLC25A20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.365	0.619	.001	24	view →
LSCC	OS	Quartile	II,III,IV	0.670	1.000	.004	11	view →
HNSC	DFS	Tertile	IV	0.827	0.536	.012	11	view →
CCRCC	DFS	Tertile	IV	0.255	0.887	.038	6	view →
UCEC	DFS	Median	II,III,IV	0.547	0.869	.041	4	view →
LUAD	OS	Median	III,IV	0.779	0.323	.024	2	view →
PDAC	DFS	Median	All	0.710	0.811	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC25A20–GBM (OS)

Open the GBM breakdown →